The efficacy and safety of tislelizumab combined with weekly nab-paclitaxel, carboplatin, and cetuximab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a real-world study

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-01-09
DOI
https://doi.org/10.3389/fimmu.2025.1708410
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The efficacy and safety of tislelizumab combined with weekly nab-paclitaxel, carboplatin, and cetuximab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a real-world study

Wenjuan Lai, F Wang, Jing Gao, Fang Yang et al.
Frontiers in Immunology
Head and Neck Cancer Studies
article

The efficacy and safety of tislelizumab combined with weekly nab-paclitaxel, carboplatin, and cetuximab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a real-world study

Wenjuan Lai, F Wang, Jing Gao, Fang Yang, Meijing Chen, Zhanyong Ouyang, Gangling Tong, Shubin Wang, Linting Zhang, Boran Cheng
article en

Abstract

No abstract available for this paper.
Frontiers in ImmunologyVol. 16
Peking University Shenzhen Hospital (CN), University of Hong Kong (HK)
Bethune Charitable Foundation, Peking University, Science, Technology and Innovation Commission of Shenzhen Municipality
No poverty
Openalex Percentile: Top 93%
Head and Neck Cancer Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.